Heterocyclic kinase inhibitors

US10280184B2 · kind B2 · utility

Assignee

• Abb Vie Inc. · US

Inventors

• Michael Friedman · Jerusalem, IL
• Philip Cox · Grayslake, US
• Kristine E. Frank · Portage, US
• Michael Z. Hoemann · Marlborough, US
• Augustine Osuma · Lindenhurst, US
• Noel S. Wilson · Kenosha, US
• Xiangdong Xu · Gurnee, US
• Kevin P. Cusack · Holden, US
• Raymond Huntley · Albany, US
• J. Martin Herold · Cambridge, US

Key dates

• Filing date: Apr 16, 2015
• Grant date: May 7, 2019
• Expiry date: Apr 16, 2035

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.